Hetero type pentamer recombinant vaccine
View Patent ↗A heteropentamer composed of a fusion monomer ( 32 ) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer ( 20 ) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A homopentamer composed of a fusion monomer including a fusion protein of an antigen derived from an envelope protein of Japanese encephalitis virus and an amino acid sequence of a monomer of a mucous membrane-binding protein. These heteropentamer and the homopentamer can be used as a vaccine.
1. A heteropentamer composed of a fusion monomer comprising a fusion protein of an antigenic amino acid sequence and the amino acid sequence of a monomer of a pentameric mucous membrane-binding protein and a nonfusion monomer of the amino acid sequence of a monomer of the mucous membrane-binding protein.
2. The heteropentamer according to claim 1 , wherein the antigenic amino acid sequence and the amino acid sequence of the mucous membrane-binding protein are joined via a linker.
3. The heteropentamer according to claim 1 , wherein the mucous membrane-binding protein is an enterotoxin B subunit or cholera toxin B subunit.
4. The heteropentamer according to claim 1 , wherein the antigenic amino acid sequence is an antigen derived from an envelope protein of Japanese encephalitis virus.
5. A nucleic acid molecule encoding the fusion monomer and the nonfusion monomer of any one of claims 1 to 4 , or a nucleic acid molecule complementary to the sequence encoding the fusion monomer and the nonfusion monomer.
6. A vector, which comprises the nucleic acid molecule of claim 5 and expresses the fusion monomer and the nonfusion monomer in a transformed host.
7. The heteropentamer of claim 4 , in which the fusion monomer comprises (1) the amino acid sequence of SEQ ID NO: 1; or (2) an amino acid sequence 90 % homologous to SEQ ID NO: 1 and having Japanese encephalitis virus antigenicity and a mucous membrane-binding property.
8. The nucleic acid molecule of claim 5 , wherein the nucleic acid encoding the fusion monomer comprises SEQ ID NO: 2.
9. A nonhuman host transformed with the vector of claim 6 .
10. An immunogenic composition comprising the heteropentamer of any one of claims 1 to 4 , or the host of claim 9 .
11. The immunogenic composition of claim 10 , which is enteric-coated and can be orally administered.
12. The immunogenic composition according to claim 11 , wherein the enteric coating comprises calcium.
13. A method for preparing a immunogenic composition, which comprises the steps of:
integrating a gene sequence encoding a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein, and a gene sequence encoding an amino acid sequence of a monomer of a mucous membrane-binding protein into a gene of a vector;
introducing the vector into a host for transformation;
expressing the vector to produce a heteropentamer composed of a fusion monomer of the fusion protein and a nonfusion monomer of the monomer; and
purifying the heteropentamer secreted in a culture solution by the host.
14. A method for intestinal immunization by orally administering the immunogenic composition of claim 10 to a human or an animal.